Functional analysis of P-glycoprotein mutants identifies predicted transmembrane domain 11 as a putative drug binding site.
The substitution of a single serine to phenylalanine residue within the predicted transmembrane domain 11 of P-glycoproteins (P-gps) encoded by mouse mdr1 (Ser941, 1S;Phe941, 1F) or mdr3 (Ser939, 3S; Phe939, 3F) strongly modulates both the overall activity and substrate specificity of the two P-gps. In cell clones expressing either wild-type (1S, 3S) or mutant P-gps (1F, 3F), we show that the modulating effect of the mutation on the levels of adriamycin (ADM) resistance detected in drug cytotoxicity assays is paralleled by a similar modulation of the intracellular accumulation and extracellular efflux of radiolabeled adriamycin ([14C]ADM) from preloaded cells. Cytofluorescence studies with ADM on live cells produce similar results and demonstrate strong nuclear ADM accumulation only in drug-sensitive LR cells and in the 1F expressing cells, with little if any accumulation in 1S, 3S, or 3F expressing cells. Drug cytotoxicity and drug transport assays carried out in the presence of verapamil or progesterone suggest that the Ser to Phe substitution also reduces the capacity of these two reversal agents to modulate P-gp activity. Labeling experiments with the photoactivatable P-gp ligands iodoarylazidoprazosin and azidopine indicate a strong reduction in binding of these photoactivatable probes to the mutant P-gps (1F, 3F) as compared to their wild-type counterparts (1S,3S). These results indicate that the studied mutations in TM11 reduce drug transport by decreasing initial drug binding to P-gp. This phenotype is opposite to that of a mutation near TM3 in human MDR1 (pst 185), where decreased drug transport is associated with increased drug binding and decreased drug release from P-gp [Safa, A. R., Stern, R. K., Choi, K., Agresti, M., Tamai, I., Metha, N. D., & Roninson, I. B. (1990) Proc. Natl. Acad. Sci. U.S.A. 87, 7225-7229].
Kajiji
S
S
Department of Cancer, Pfizer Central Research, Groton, Connecticut 06340.
Talbot
F
F
Grizzuti
K
K
Van Dyke-Phillips
V
V
Agresti
M
M
Safa
A R
AR
Gros
P
P
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000345:Affinity Labels; D000595:Amino Acid Sequence; D000818:Animals; D001386:Azides / Q000378:metabolism; D001665:Binding Sites; D001692:Biological Transport; D016466:CHO Cells; D002462:Cell Membrane / Q000378:metabolism; D003001:Cloning, Molecular; D003078:Colchicine / Q000378:metabolism; D006224:Cricetinae; D003609:Dactinomycin / Q000378:metabolism; D004317:Doxorubicin; D004351:Drug Resistance / Q000235:genetics*; D006096:Gramicidin / Q000378:metabolism; D007457:Iodine Radioisotopes; D007700:Kinetics; D008562:Membrane Glycoproteins / Q000235:genetics* / Q000378:metabolism*; D051379:Mice; D016297:Mutagenesis, Site-Directed; D010649:Phenylalanine; D011224:Prazosin / Q000031:analogs & derivatives / Q000378:metabolism; D012694:Serine; D014162:Transfection; D014747:Vinblastine / Q000378:metabolism
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000345:Affinity Labels; D001386:Azides; D007457:Iodine Radioisotopes; D008562:Membrane Glycoproteins; D006096:Gramicidin; D003609:Dactinomycin; D012694:Serine; D010649:Phenylalanine; D014747:Vinblastine; D004317:Doxorubicin; C041552:azidoprazosin; D003078:Colchicine; D011224:Prazosin